JP2022515193A - アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 - Google Patents
アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 Download PDFInfo
- Publication number
- JP2022515193A JP2022515193A JP2021536024A JP2021536024A JP2022515193A JP 2022515193 A JP2022515193 A JP 2022515193A JP 2021536024 A JP2021536024 A JP 2021536024A JP 2021536024 A JP2021536024 A JP 2021536024A JP 2022515193 A JP2022515193 A JP 2022515193A
- Authority
- JP
- Japan
- Prior art keywords
- double
- nucleotides
- rnai agent
- app
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 COC[C@](C1)N(*)CC1OC Chemical compound COC[C@](C1)N(*)CC1OC 0.000 description 10
- HXJJFAFABXEKLD-SSDOTTSWSA-N B[C@@H](C1)OC(COC)=C1OC Chemical compound B[C@@H](C1)OC(COC)=C1OC HXJJFAFABXEKLD-SSDOTTSWSA-N 0.000 description 1
- XOJVXYVKUFVBQE-UHFFFAOYSA-N CC[n](cc1)c(cc2)c1cc2[N+]([O-])=O Chemical compound CC[n](cc1)c(cc2)c1cc2[N+]([O-])=O XOJVXYVKUFVBQE-UHFFFAOYSA-N 0.000 description 1
- ORZQZDFOABYORG-UHFFFAOYSA-N COCC(OCC1)=C1OC Chemical compound COCC(OCC1)=C1OC ORZQZDFOABYORG-UHFFFAOYSA-N 0.000 description 1
- AUIBUIVVOOFMLT-UHFFFAOYSA-N COCC(OCC1OC)=C1OC Chemical compound COCC(OCC1OC)=C1OC AUIBUIVVOOFMLT-UHFFFAOYSA-N 0.000 description 1
- AVCGGVFMLBZIGD-JGVFFNPUSA-N COC[C@H]1OCCC[C@@H]1OC Chemical compound COC[C@H]1OCCC[C@@H]1OC AVCGGVFMLBZIGD-JGVFFNPUSA-N 0.000 description 1
- LSKCTDOPSVEIPU-UHFFFAOYSA-N C[n]1c(nc(N)nc2)c2nc1 Chemical compound C[n]1c(nc(N)nc2)c2nc1 LSKCTDOPSVEIPU-UHFFFAOYSA-N 0.000 description 1
- CQYLGSKQLBWLHF-UHFFFAOYSA-N Cc(c(F)c1)cc(C)c1F Chemical compound Cc(c(F)c1)cc(C)c1F CQYLGSKQLBWLHF-UHFFFAOYSA-N 0.000 description 1
- DRJSEGTWOQNMSY-UHFFFAOYSA-N Cc1cccc2c1nc[n]2C Chemical compound Cc1cccc2c1nc[n]2C DRJSEGTWOQNMSY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024090554A JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781774P | 2018-12-19 | 2018-12-19 | |
| US62/781,774 | 2018-12-19 | ||
| US201962862472P | 2019-06-17 | 2019-06-17 | |
| US62/862,472 | 2019-06-17 | ||
| US201962928795P | 2019-10-31 | 2019-10-31 | |
| US62/928,795 | 2019-10-31 | ||
| PCT/US2019/067449 WO2020132227A2 (en) | 2018-12-19 | 2019-12-19 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090554A Division JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515193A true JP2022515193A (ja) | 2022-02-17 |
| JP2022515193A5 JP2022515193A5 (cg-RX-API-DMAC7.html) | 2022-12-26 |
Family
ID=71101909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536024A Pending JP2022515193A (ja) | 2018-12-19 | 2019-12-19 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
| JP2024090554A Pending JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090554A Pending JP2024113043A (ja) | 2018-12-19 | 2024-06-04 | アミロイド前駆体タンパク質(APP)RNAi薬剤組成物およびその使用方法 |
Country Status (20)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518564A (ja) * | 2021-05-11 | 2024-05-01 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 中枢神経系のニューロンを標的とするための脂質コンジュゲーション |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2854880B1 (en) | 2012-05-29 | 2019-03-13 | 3M Innovative Properties Company | Absorbent article comprising polymeric foam |
| WO2019169243A1 (en) | 2018-03-02 | 2019-09-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
| BR112021002440A2 (pt) | 2018-08-10 | 2021-05-04 | University Of Massachusetts | oligonucleotídeos modificados visando snps |
| WO2021012082A1 (zh) * | 2019-07-19 | 2021-01-28 | 莫丁丁 | β—淀粉样蛋白环状核糖核酸、多肽及其应用 |
| JP2019213978A (ja) * | 2019-09-30 | 2019-12-19 | 株式会社三洋物産 | 遊技機 |
| MX2023001222A (es) | 2020-07-28 | 2023-04-26 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de app. |
| US20240294906A1 (en) * | 2020-07-29 | 2024-09-05 | Alnylam Pharmaceuticals, Inc. | Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases |
| WO2022165172A1 (en) * | 2021-01-29 | 2022-08-04 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing amyloid precursor protein (app) |
| US20240175028A1 (en) * | 2021-03-05 | 2024-05-30 | Alnylam Pharmaceuticals, Inc | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA |
| WO2023283403A2 (en) * | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| JP2024534961A (ja) * | 2021-09-10 | 2024-09-26 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 拡大したエンドソームによって特徴付けられる疾患を処置または予防するためのAPP iRNA組成物およびその使用方法 |
| KR20240067943A (ko) | 2021-09-24 | 2024-05-17 | 알닐람 파마슈티칼스 인코포레이티드 | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 |
| JP2024542125A (ja) * | 2021-10-28 | 2024-11-13 | ザ・ホンコン・ユニバーシティー・オブ・サイエンス・アンド・テクノロジー | アミロイド病変に対する治療アプローチとしてのapp発現のcrispr媒介性操作 |
| WO2023081500A2 (en) * | 2021-11-08 | 2023-05-11 | Dicerna Pharmaceuticals, Inc. | RNAi OLIGONUCLEOTIDE CONJUGATES |
| TW202335674A (zh) * | 2021-11-05 | 2023-09-16 | 美商黛瑟納製藥公司 | 靶定中樞神經系統的星狀細胞之脂質結合物 |
| TW202340462A (zh) * | 2021-11-05 | 2023-10-16 | 美商黛瑟納製藥公司 | 靶定中樞神經系統的寡樹突細胞之脂質結合物 |
| US20230392146A1 (en) * | 2022-03-11 | 2023-12-07 | University Of Massachusetts | Oligonucleotides for app modulation |
| WO2023207615A1 (zh) * | 2022-04-26 | 2023-11-02 | 南京明德新药研发有限公司 | 一类含由天然核苷酸组成突出端的双链RNAi化合物 |
| WO2023224979A1 (en) * | 2022-05-16 | 2023-11-23 | University Of Massachusetts | Optimized sirna scaffolds |
| WO2023230465A1 (en) * | 2022-05-23 | 2023-11-30 | Switch Therapeutics Inc. | Antisense oligonucleotides |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| WO2025007961A1 (zh) | 2023-07-06 | 2025-01-09 | 大睿生物 | 调控AGT表达的dsRNA分子 |
| US20250064958A1 (en) * | 2023-08-22 | 2025-02-27 | Eli Lilly And Company | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENTS |
| WO2025045195A1 (zh) * | 2023-08-31 | 2025-03-06 | 上海拓界生物医药科技有限公司 | 靶向APP的RNAi剂及其医药用途 |
| CN120077136A (zh) * | 2023-09-28 | 2025-05-30 | 广州必贝特医药股份有限公司 | 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用 |
| TW202516009A (zh) * | 2023-10-10 | 2025-04-16 | 大陸商上海舶望製藥有限公司 | 抑制澱粉樣前體蛋白(app)表達的組合物和方法 |
| WO2025228429A1 (zh) * | 2024-04-30 | 2025-11-06 | 北京安龙生物医药有限公司 | 靶向淀粉样前体蛋白基因的寡核苷酸及其用途 |
| CN118979036B (zh) * | 2024-08-01 | 2025-08-19 | 北京尧景基因技术有限公司 | 抑制APP基因表达的siRNA及其缀合物和应用 |
| CN121175422A (zh) * | 2024-10-08 | 2025-12-19 | 北京安龙生物医药有限公司 | 修饰的双链寡核苷酸及其缀合物和组合物 |
| WO2026085164A2 (en) | 2024-10-16 | 2026-04-23 | Alnylam Pharmaceuticals, Inc. | Snca irna formulations and methods of use thereof |
| WO2026092658A2 (en) * | 2024-10-31 | 2026-05-07 | Sanegene Bio Usa Inc. | Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003350A2 (en) * | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER’S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209179A1 (en) * | 2000-08-30 | 2005-09-22 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| US20080032942A1 (en) * | 2000-08-30 | 2008-02-07 | Mcswiggen James | RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA) |
| CA2489174C (en) | 2002-07-10 | 2013-02-05 | Thomas Tuschl | Rna-interference by single-stranded rna molecules |
| US7851615B2 (en) * | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
| GB0324854D0 (en) * | 2003-10-24 | 2003-11-26 | Expresson Biosystems Ltd | App/ena antisense |
| EP2239328A3 (en) * | 2005-08-18 | 2011-01-05 | Alnylam Pharmaceuticals Inc. | Methods and compositions for treating neurological disease |
| JP5252622B2 (ja) * | 2007-01-17 | 2013-07-31 | 独立行政法人産業技術総合研究所 | 高いヌクレアーゼ耐性と優れたrna干渉効果を発現可能な二本鎖rna |
| WO2009113579A1 (ja) * | 2008-03-11 | 2009-09-17 | 学校法人埼玉医科大学 | 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 |
| WO2011072091A1 (en) * | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| US20130253168A1 (en) * | 2010-08-31 | 2013-09-26 | Steven L. Colletti | Novel single chemical entities and methods for delivery of oligonucleotides |
| US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| US9663784B2 (en) * | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| BR112015013105B1 (pt) * | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| US10004814B2 (en) * | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| TWI864340B (zh) * | 2014-10-10 | 2024-12-01 | 美商艾爾妮蘭製藥公司 | 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法 |
| TWI769565B (zh) * | 2014-11-10 | 2022-07-01 | 美商阿尼拉製藥公司 | B型肝炎病毒(HBV)iRNA組成物及其用途方法 |
| EP3362562B1 (en) * | 2015-10-16 | 2026-07-22 | Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (LUMC) | Antisense oligonucleotides for use in treating alzheimer's disease |
| CA3098623A1 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| JP7557469B2 (ja) * | 2019-01-29 | 2024-09-27 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Appの発現を低減するための化合物及び方法 |
| EP3983077A4 (en) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM |
-
2019
- 2019-12-19 AU AU2019405783A patent/AU2019405783B2/en active Active
- 2019-12-19 TW TW108146697A patent/TW202039844A/zh unknown
- 2019-12-19 EP EP19900781.6A patent/EP3898979A4/en active Pending
- 2019-12-19 MX MX2021007570A patent/MX2021007570A/es unknown
- 2019-12-19 JP JP2021536024A patent/JP2022515193A/ja active Pending
- 2019-12-19 SG SG11202105886QA patent/SG11202105886QA/en unknown
- 2019-12-19 PE PE2021000927A patent/PE20211420A1/es unknown
- 2019-12-19 BR BR112021011895-0A patent/BR112021011895A2/pt unknown
- 2019-12-19 CN CN201980092566.2A patent/CN113454222B/zh active Active
- 2019-12-19 KR KR1020217022070A patent/KR20210111780A/ko active Pending
- 2019-12-19 CR CR20210393A patent/CR20210393A/es unknown
- 2019-12-19 MY MYPI2021003429A patent/MY206230A/en unknown
- 2019-12-19 CN CN202510065418.9A patent/CN120041447A/zh active Pending
- 2019-12-19 WO PCT/US2019/067449 patent/WO2020132227A2/en not_active Ceased
- 2019-12-19 CA CA3124090A patent/CA3124090A1/en active Pending
- 2019-12-19 PH PH1/2021/551482A patent/PH12021551482A1/en unknown
-
2020
- 2020-07-09 US US16/925,286 patent/US11034957B2/en active Active
-
2021
- 2021-05-07 US US17/314,909 patent/US20220002724A1/en active Pending
- 2021-06-09 IL IL283852A patent/IL283852A/en unknown
- 2021-06-17 CL CL2021001605A patent/CL2021001605A1/es unknown
- 2021-06-18 DO DO2021000126A patent/DOP2021000126A/es unknown
- 2021-07-14 CO CONC2021/0009163A patent/CO2021009163A2/es unknown
-
2024
- 2024-06-04 JP JP2024090554A patent/JP2024113043A/ja active Pending
-
2025
- 2025-09-18 DO DO2025000233A patent/DOP2025000233A/es unknown
-
2026
- 2026-06-15 AU AU2026204572A patent/AU2026204572A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003350A2 (en) * | 2003-06-27 | 2005-01-13 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER’S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518564A (ja) * | 2021-05-11 | 2024-05-01 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 中枢神経系のニューロンを標的とするための脂質コンジュゲーション |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220002724A1 (en) | 2022-01-06 |
| CN113454222B (zh) | 2025-01-14 |
| AU2019405783B2 (en) | 2026-03-26 |
| PE20211420A1 (es) | 2021-08-03 |
| CN113454222A (zh) | 2021-09-28 |
| SG11202105886QA (en) | 2021-07-29 |
| CL2021001605A1 (es) | 2021-12-24 |
| PH12021551482A1 (en) | 2022-04-11 |
| AU2026204572A1 (en) | 2026-07-16 |
| WO2020132227A2 (en) | 2020-06-25 |
| MY206230A (en) | 2024-12-05 |
| EP3898979A4 (en) | 2022-10-12 |
| IL283852A (en) | 2021-07-29 |
| US20200339991A1 (en) | 2020-10-29 |
| TW202039844A (zh) | 2020-11-01 |
| EP3898979A2 (en) | 2021-10-27 |
| BR112021011895A2 (pt) | 2021-09-08 |
| US11034957B2 (en) | 2021-06-15 |
| MX2021007570A (es) | 2021-08-24 |
| DOP2025000233A (es) | 2025-12-15 |
| CR20210393A (es) | 2021-10-27 |
| WO2020132227A3 (en) | 2020-07-30 |
| CN120041447A (zh) | 2025-05-27 |
| KR20210111780A (ko) | 2021-09-13 |
| JP2024113043A (ja) | 2024-08-21 |
| CA3124090A1 (en) | 2020-06-25 |
| AU2019405783A1 (en) | 2021-07-01 |
| CO2021009163A2 (es) | 2021-10-29 |
| DOP2021000126A (es) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11034957B2 (en) | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof | |
| TWI897902B (zh) | 人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法 | |
| JP7844347B2 (ja) | アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法 | |
| CN116234585A (zh) | 微管相关蛋白TAU(MAPT)iRNA剂组合物及其使用方法 | |
| JP2026028255A (ja) | ハンチンチン(HTT)iRNA剤組成物およびその使用方法 | |
| KR20240067943A (ko) | 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법 | |
| US20240117349A1 (en) | iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP) | |
| JP7826211B2 (ja) | ロイシンリッチリピートキナーゼ2(LRRK2)iRNA剤組成物およびその使用方法 | |
| TW202305131A (zh) | 用於治療或預防超氧歧化酶1-(SOD1-)相關的神經退化疾病的超氧歧化酶1(SOD1)iRNA組成物及其使用方法 | |
| JP2024528503A (ja) | ロイシンリッチリピートキナーゼ2(LRRK2)iRNA剤組成物およびその使用方法 | |
| JP2024512635A (ja) | ハンチンチン(HTT)iRNA剤組成物およびその使用方法 | |
| JP2024509783A (ja) | プリオンタンパク質(prnp)irna組成物およびその使用方法 | |
| JP2025507372A (ja) | 微小管関連タンパク質タウ(MAPT)iRNA剤組成物およびその使用方法 | |
| JP2025516321A (ja) | アクチン結合LIMタンパク質3(ABLIM3)iRNA剤組成物およびその使用方法 | |
| CN117561335A (zh) | 富含亮氨酸的重复激酶2(LRRK2)iRNA药剂组合物和其使用方法 | |
| TW202334418A (zh) | 杭丁頓(HTT)iRNA劑組成物及其使用方法 | |
| EA048839B1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ СРЕДСТВА ДЛЯ RNAi В ОТНОШЕНИИ БЕЛКА-ПРЕДШЕСТВЕННИКА АМИЛОИДА (APP) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN118176300A (zh) | 亨廷顿(HTT)iRNA剂组合物及其使用方法 | |
| EA051373B1 (ru) | Композиции агента irna аполипопротеина е (арое) и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221216 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231204 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240301 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240726 |